83 FR 48320 - Office of the Director, National Institutes of Health; Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Federal Register Volume 83, Issue 185 (September 24, 2018)

Page Range		48320-48320
FR Document		2018-20665

Federal Register, Volume 83 Issue 185 (Monday, September 24, 2018)

[Federal Register Volume 83, Number 185 (Monday, September 24, 2018)]
[Notices]
[Page 48320]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-20665]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Advisory Committee 
on Research on Women's Health.
    The meeting will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting. The meeting will also be 
videocast and can be accessed from the NIH Videocasting and Podcasting 
website (http://videocast.nih.gov/).

    Name of Committee: Advisory Committee on Research on Women's 
Health.
    Date: October 23, 2018.
    Time: 9:00 a.m. to 4:00 p.m.
    Agenda: Opening Remarks, Director's Report, Scientific 
Presentations, ORWH SCORE Program Update, and Strategic Plan Launch.
    Place: National Institutes of Health, Building 31, 6th Floor, 
Conference Room 10, 31 Center Drive, Bethesda, MD 20892.
    Contact Person: Elizabeth Spencer, R.N., Deputy Director, Office 
of Research on Women's Health, Executive Secretary, ACRWH, National 
Institutes of Health, 6707 Democracy Blvd., Room 7W444, Bethesda, MD 
20817, 301-402-1770, [email protected].

    Any member of the public interested in presenting oral comments 
to the committee may notify the Contact Person listed on this notice 
at least 10 days in advance of the meeting. Interested individuals 
and representatives of organizations may submit a letter of intent, 
a brief description of the organization represented, and a short 
description of the oral presentation. Only one representative of an 
organization may be allowed to present oral comments and if accepted 
by the committee, presentations may be limited to five minutes. Both 
printed and electronic copies are requested for the record. In 
addition, any interested person may file written comments with the 
committee by forwarding their statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: https://orwh.od.nih.gov/, where an agenda and any additional 
information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: September 18, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-20665 Filed 9-21-18; 8:45 am]
 BILLING CODE 4140-01-P

48320 Federal Register / Vol. 83, No. 185 / Monday, September 24, 2018 / Notices

NIAID inventors have identified a multi- Dated: September 18, 2018. business or professional affiliation of the
valent tolerogen (MMPt), which can Suzanne M. Frisbie, interested person.
specifically elicit RICD of the activated, Deputy Director, Technology Transfer and In the interest of security, NIH has
Intellectual Property Office, National Institute instituted stringent procedures for entrance
disease causing autoimmune T cells onto the NIH campus. All visitor vehicles,
without compromising the general T of Allergy and Infectious Diseases.
including taxicabs, hotel, and airport shuttles
cell-dependent immunity in the host. [FR Doc. 2018–20664 Filed 9–21–18; 8:45 am] will be inspected before being allowed on
Animal studies have demonstrated that BILLING CODE 4140–01–P campus. Visitors will be asked to show one
MMPt exerts robust therapeutic effects form of identification (for example, a
on both monophasic as well as government-issued photo ID, driver’s license,
DEPARTMENT OF HEALTH AND or passport) and to state the purpose of their
relapsing-remitting type of the disease, visit.
HUMAN SERVICES
indicating its medical applicability for Information is also available on the
treating MS patients with active disease. National Institutes of Health Institute’s/Center’s home page: https://
NIAID is seeking partners to develop orwh.od.nih.gov/, where an agenda and any
this multi-valent peptide to improve its Office of the Director, National additional information for the meeting will
efficacy for use in clinical trials. Institutes of Health; Notice of Meeting be posted when available.
(Catalogue of Federal Domestic Assistance
This technology is available for Pursuant to section 10(a) of the Program Nos. 93.14, Intramural Research
licensing for commercial development Federal Advisory Committee Act, as Training Award; 93.22, Clinical Research
in accordance with 35 U.S.C. 209 and 37 amended, notice is hereby given of a Loan Repayment Program for Individuals
CFR part 404, as well as for further meeting of the Advisory Committee on from Disadvantaged Backgrounds; 93.232,
development and evaluation under a Research on Women’s Health. Loan Repayment Program for Research
research collaboration. The meeting will be open to the Generally; 93.39, Academic Research
public as indicated below, with Enhancement Award; 93.936, NIH Acquired
Potential Commercial Applications: attendance limited to space available. Immunodeficiency Syndrome Research Loan
Individuals who plan to attend and Repayment Program; 93.187, Undergraduate
• Therapeutics Scholarship Program for Individuals from
need special assistance, such as sign Disadvantaged Backgrounds, National
Competitive Advantages: language interpretation or other Institutes of Health, HHS)
• Tolerogen induced elimination of reasonable accommodations, should
notify the Contact Person listed below Dated: September 18, 2018.
activated autoimmune T cells will Ronald J. Livingston, Jr.,
overcome the fatal side effects of in advance of the meeting. The meeting
will also be videocast and can be Program Analyst, Office of Federal Advisory
current therapies Committee Policy.
accessed from the NIH Videocasting and
• Treatment of all types of MS patients Podcasting website (http:// [FR Doc. 2018–20665 Filed 9–21–18; 8:45 am]

Development Stage: videocast.nih.gov/). BILLING CODE 4140–01–P

Name of Committee: Advisory Committee
• Preclinical (In vitro and in vivo on Research on Women’s Health.
animal studies) Date: October 23, 2018. DEPARTMENT OF HEALTH AND
Time: 9:00 a.m. to 4:00 p.m. HUMAN SERVICES
Inventors: Dr. Michael J. Lenardo Agenda: Opening Remarks, Director’s
(NIAID), Dr. Lixin Zheng (NIAID), Dr. Report, Scientific Presentations, ORWH National Institutes of Health
Jian Li (NIAID), Dr. Jae Lee (NIAID), and SCORE Program Update, and Strategic Plan
Dr. Wei Lu (NIAID). Launch. Office of the Director, National
Intellectual Property: HHS Reference Place: National Institutes of Health, Institutes of Health; Notice of Meeting
Building 31, 6th Floor, Conference Room 10,
No. E–064–2015, U.S. Provisional Patent 31 Center Drive, Bethesda, MD 20892. Pursuant to section 10(a) of the
Application Numbers: 62/130,285 filed Contact Person: Elizabeth Spencer, R.N., Federal Advisory Committee Act, as
March 9, 2015 and 62/219,851 filed Deputy Director, Office of Research on amended, notice is hereby given of a
September 17, 2015, and US PCT Women’s Health, Executive Secretary, meeting of the NIH Clinical Center
application PCT/US2016/021571 filed ACRWH, National Institutes of Health, 6707
Democracy Blvd., Room 7W444, Bethesda,
Research Hospital Board.
on March 9, 2016. Entered National The meeting will be open to the
MD 20817, 301–402–1770,
Stage filing in US, EU, Canada, and elizabeth.spencer@nih.gov. public, with attendance limited to space
Australia. Any member of the public interested in available. Individuals who plan to
Licensing Contact: Yogikala Prabhu, presenting oral comments to the committee attend and need special assistance, such
Ph.D., 301–761–7789; prabhuyo@ may notify the Contact Person listed on this as sign language interpretation or other
niaid.nih.gov. notice at least 10 days in advance of the reasonable accommodations, should
meeting. Interested individuals and notify the Contact Person listed below
Collaborative Research Opportunity: representatives of organizations may submit in advance of the meeting.
The National Institute of Allergy and a letter of intent, a brief description of the
Infectious Diseases is seeking statements organization represented, and a short Name of Committee: NIH Clinical Center
of capability or interest from parties description of the oral presentation. Only one Research Hospital Board.
representative of an organization may be Date: October 19, 2018.
interested in collaborative research to Time: 9:00 a.m. to 3:25 p.m.
allowed to present oral comments and if
further develop, evaluate or accepted by the committee, presentations Agenda: Discussion of Patient Safety.
amozie on DSK3GDR082PROD with NOTICES1

commercialize the MMPt peptide to may be limited to five minutes. Both printed Place: National Institutes of Health,
improve its efficacy for use in clinical and electronic copies are requested for the Building 31, 6th Floor, Room: 6C6, 31 Center
trials. record. In addition, any interested person Drive, Bethesda, MD 20892.
may file written comments with the Contact Person: Gretchen Wood, Staff
For collaboration opportunities, committee by forwarding their statement to Assistant, Office of the Director, National
please contact Yogikala Prabhu, Ph.D., the Contact Person listed on this notice. The Institutes of Health, One Center Drive,
301–761–7789; prabhuyo@ statement should include the name, address, Building 1, Bethesda, MD 20892, 301–496–
niaid.nih.gov. telephone number and when applicable, the 4272, woodgs@nih.gov.

VerDate Sep<11>2014 17:40 Sep 21, 2018 Jkt 244001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\24SEN1.SGM 24SEN1

Document Created: 2018-09-22 00:33:15
Document Modified: 2018-09-22 00:33:15

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		October 23, 2018.
FR Citation		83 FR 48320